Project Details
Description
In this proposal, we will investigate the therapeutic properties of recombinant fusion protein directed to tumor-associated antigen, IL13Rα2, via scFv47 attached to a mutated form of superantigen staphylococcal enterotoxin E (SEA/E-120) in murine glioma models of disease.
The NeoTx will provide purified recombinant protein and corresponding negative control protein for analysis.
The Northwestern University (PI: Irina Balyasnikova) will perform validations of the activity of the recombinant protein in murine models of glioblastoma in vitro and in vivo.
| Status | Finished |
|---|---|
| Effective start/end date | 12/1/20 → 2/28/23 |
Funding
- Neotx Holdings Ltd. (Amendment #2)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.